Combining Ensemble Learning with a Fragment-Based Topological Approach To Generate New Molecular Diversity in Drug Discovery: In Silico Design of Hsp90 Inhibitors

被引:31
|
作者
Speck-Planche, Alejandro [1 ]
机构
[1] Hosp del Mar, Res Program Biomed Informat GRIB, Med Res Inst IMIM, Barcelona 08003, Spain
来源
ACS OMEGA | 2018年 / 3卷 / 11期
关键词
QUADRATIC FINGERPRINTS; PREDICTION; MODEL; QSAR; POTENT; ATOM; PERMEABILITY; MACHINE; INDEXES; CANCER;
D O I
10.1021/acsomega.8b02419
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Machine learning methods have revolutionized modern science, providing fast and accurate solutions to multiple problems. However, they are commonly treated as "black boxes". Therefore, in important scientific fields such as medicinal chemistry and drug discovery, machine learning methods are restricted almost exclusively to the task of performing predictions of large and heterogeneous data sets of chemicals. The lack of interpretability prevents the full exploitation of the machine learning models as generators of new chemical knowledge. This work focuses on the development of an ensemble learning model for the prediction and design of potent dual heat shock protein 90 (Hsp90) inhibitors. The model displays accuracy higher than 80% in both training and test sets. To use the ensemble model as a generator of new chemical knowledge, three steps were followed. First, a physicochemical and/or structural interpretation was provided for each molecular descriptor present in the ensemble learning model. Second, the term "pseudolinear equation" was introduced within the context of machine learning to calculate the relative quantitative contributions of different molecular fragments to the inhibitory activity against the two Hsp90 isoforms studied here. Finally, by assembling the fragments with positive contributions, new molecules were designed, being predicted as potent Hsp90 inhibitors. According to Lipinski's rule of five, the designed molecules were found to exhibit potentially good oral bioavailability, a primordial property that chemicals must have to pass early stages in drug discovery. The present approach based on the combination of ensemble learning and fragment-based topological design holds great promise in drug discovery, and it can be adapted and applied to many different scientific disciplines.
引用
收藏
页码:14704 / 14716
页数:13
相关论文
共 7 条
  • [1] Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery
    Leon, Roberto
    Soto-Delgado, Jorge
    Montero, Elizabeth
    Vargas, Matias
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [2] Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design
    Chang, Chun-Feng
    Lin, Wen-Hsing
    Ke, Yi-Yu
    Lin, Yih-Shyan
    Wang, Wen-Chieh
    Chen, Chun-Hwa
    Kuo, Po-Chu
    Hsu, John T. A.
    Uang, Biing-Jiun
    Hsieh, Hsing-Pang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 124 : 186 - 199
  • [3] Fragment-based Drug Design of Antitumoral Molecules Polo-like Kinase 1 Inhibitors: In-silico Approach
    Attoui, Ayoub
    Sobhi, Widad
    Hammoudi, Nour El Houda
    Benguerba, Yacine
    LETTERS IN DRUG DESIGN & DISCOVERY, 2021, 18 (08) : 779 - 794
  • [4] Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design
    Yu, Wenying
    Xiao, Hui
    Lin, Jiayuh
    Li, Chenglong
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) : 4402 - 4412
  • [5] Combined in Silico and Experimental Approach for Drug Design: The Binding Mode of Peptidic and Non-Peptidic Inhibitors to Hsp90 N-Terminal Domain
    Tomaselli, Simona
    Meli, Massimiliano
    Plescia, Janet
    Zetta, Lucia
    Altieri, Dario C.
    Colombo, Giorgio
    Ragona, Laura
    CHEMICAL BIOLOGY & DRUG DESIGN, 2010, 76 (05) : 382 - 391
  • [6] Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
    Davies, Nicholas G. M.
    Browne, Helen
    Davis, Ben
    Drysdale, Martin J.
    Foloppe, Nicolas
    Geoffrey, Stephanie
    Gibbons, Ben
    Hart, Terance
    Hubbard, Roderick
    Jensen, Michael Rugaard
    Mansell, Howard
    Massey, Andrew
    Matassova, Natalia
    Moore, Jonathan D.
    Murray, James
    Pratt, Robert
    Ray, Stuart
    Robertson, Alan
    Roughley, Stephen D.
    Schoepfer, Joseph
    Scriven, Kirsten
    Simmonite, Heather
    Stokes, Stephen
    Surgenor, Allan
    Webb, Paul
    Wood, Mike
    Wright, Lisa
    Brough, Paul
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (22) : 6770 - 6789
  • [7] Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
    Woodhead, Andrew J.
    Angove, Hayley
    Carr, Maria G.
    Chessari, Gianni
    Congreve, Miles
    Coyle, Joseph E.
    Cosme, Jose
    Graham, Brent
    Day, Philip J.
    Downham, Robert
    Fazal, Lynsey
    Feltell, Ruth
    Figueroa, Eva
    Frederickson, Martyn
    Lewis, Jonathan
    McMenamin, Rachel
    Murray, Christopher W.
    O'Brien, M. Alistair
    Parra, Lina
    Patel, Sahil
    Phillips, Theresa
    Rees, David C.
    Rich, Sharna
    Smith, Donna-Michelle
    Trewartha, Gary
    Vinkovic, Mladen
    Williams, Brian
    Woolford, Alison J. -A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (16) : 5956 - 5969